A pharmaceutical combination comprising a) the compound 5- (2,6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof and b) an mTOR inhibitor that is everolimus.Una combinación farmacéutica que comprende a) el compuesto 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina, o un estereoisómero, tautómero o sal farmacéuticamente aceptable del mismo y b) un inhibidor de mTOR que es everolimus.
